Clinical Trials Logo

Clinical Trial Summary

Experimental Drug: Porcine sodium heparin, injectable solution - 5,000 IU/ 0.25 mL; Blau Farmacêutica S/A. Comparator Drug: Heparin Sodium Injection, USP, injectable solution - 5,000 IU/ 0.5 mL; Fresenius Kabi Lake Zurich. Evaluate the equivalence in terms of pharmacodynamics of heparin sodium (test product) and Heparin Sodium Injection, USP (comparator product). The clinical trial will last approximately 08 weeks and the study population will consist of 68 healthy research participants, 34 women and 34 men


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05788913
Study type Interventional
Source Blau Farmaceutica S.A.
Contact Blau Farmacêutica
Phone 114615-9400
Email pesquisaclinica@blau.com
Status Not yet recruiting
Phase Phase 1
Start date June 1, 2023
Completion date September 30, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04010955 - Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON)
Recruiting NCT04673695 - A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 Phase 1
Completed NCT03893591 - A Prospective Study to Examine the Need to Adjust the Dose of Apixaban When Used in Atrial Fibrillation and Obesity
Completed NCT03895502 - Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study Phase 4
Completed NCT03154489 - Effectiveness of a Multidisciplinary Medication Review With Follow-up for Patients Treated With Coumarin Anticoagulants in Primary Care N/A
Completed NCT04305821 - Medico-economic Interest of the Protein S100b in Mild Head Trauma Under Anti-thrombotics
Recruiting NCT06020560 - Study of Low Molecular Weight Heparins Phase 4
Not yet recruiting NCT05788900 - Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Intravenous Administration Phase 1
Terminated NCT03172546 - Determinants of Oral Anticoagulants' Activity
Not yet recruiting NCT04592822 - A Single Dose Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition Phase 1
Recruiting NCT03772457 - Predictive Value of Infarction Volume on Hemorrhagic Transformation in Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban
Completed NCT03323320 - Evaluation of Patient's Knowledge of Their NACO Treatment N/A
Recruiting NCT04257487 - Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study) Phase 3
Completed NCT04272723 - Management of Venous Thromboembolism in France: a National Survey Among Vascular Medicine Physicians
Recruiting NCT04867200 - A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Volunteers Phase 1